Source: HandofMoscow | June 3, 2018
by Andry Kut
The arbitration court of Moscow satisfied the request of the Russian pharmaceutical company “Ukrenergo” on the issuance of a license to use a patent of the American Corporation Celgene in connection with a dependent invention. As noted by RBC, this is the first in the history of Russia such a decision.
Lenalidomide — antitumor and immunostimulatory drug for the treatment of leprosy, tuberculosis, AIDS and multiple myeloma. According to the state register, the domestic lenalidomide “is much cheaper than the American original.”
“Lenalidomide-Nativ” was registered in the state register in August 2016, March 2017 and has the patent for this medicine, the American company Celgene has filed a lawsuit to “Native” with the requirement to forbid her to produce and market your lenalidomide. The defendants appealed to Celgene a counterclaim in which he asked the court to allow “Native” forced to license this drug.
According to the court, “Nativ” will list license fees for the use of the patent.
Deputy Director of the company Julia Gerasimova said that copyright holders frequently abuse their position, and this greatly hinders the development of production and supply of socially important medicines in Russia, the same position is shared by the Federal Antimonopoly service of Russia.
Don't trade our lives away 